NVO Wegovy: 40% of Young Kids Off Obesity in STEP Young

Novo Nordisk (NYSE: NVO) reported first results from the Phase 3 STEP Young trial, showing once-weekly Wegovy helped 40.4% of children aged 6 to under 12 with obesity move below the obesity threshold after 68 weeks, versus 0% on placebo.

The trial enrolled 165 children, most with severe disease at baseline: more than 85% had class II or III obesity. Children received either 1.7 mg or 2.4 mg of semaglutide weekly, based on starting weight, plus a reduced-calorie diet and increased activity. Semaglutide mimics GLP-1, the gut hormone that regulates blood sugar and appetite.

The headline number is unusually clean for an obesity trial: two in five treated children left the obesity category entirely within about a year, while none in the placebo group did. Novo said detailed data will be presented at ObesityWeek 2026, November 14 to 17.

This is the first Phase 3 win for a GLP-1 drug in the 6-to-12 age group. Wegovy is already approved in the US for weight management in people 12 and older, so the readout extends Novo’s pediatric franchise into younger children at a time when childhood obesity tracks into adult obesity and early comorbidities. Off-label GLP-1 prescribing in younger kids is already climbing, with one study finding prescriptions in children aged 8 to 11 jumped from 0.03% in 2019 to 9.3% in 2026.

The mechanism is the same one that made semaglutide a household name: it slows gastric emptying and suppresses appetite. The open question in children has always been whether early intervention changes the long-term trajectory of obesity. Roughly 20.7% of US children aged 6 to 11 have obesity, and weight-related complications appear earlier and more severely in people who develop it young, so a pediatric label carries real public-health weight.

The readout lands during a rough stretch for Novo, which has lost ground to Eli Lilly in obesity and earlier this month canceled several cardiovascular trials in its ziltivekimab program. Investors largely shrugged: the readout is a label expansion, not a new approval, and Novo’s ADR closed at $38.80.

The honest risk is the timeline. This is a label expansion for an already-approved drug, so the near-term catalyst is a regulatory filing rather than a decision, and detailed safety data, including any gastrointestinal effects in younger children, will matter when the full dataset arrives.

What to watch next is the ObesityWeek data presentation and any regulatory submission for the pediatric label. See how the GLP-1 field is stacking up in the obesity market breakdown. Read Novo’s announcement here.

What It Means for the Trade

The 0% placebo comparator is the number that matters: in a pediatric obesity trial, no placebo child left the obesity category at all, while two of five treated children did. That is an unusually clean efficacy signal for a field used to arguing over single-digit placebo-adjusted differences, and it lands in a market with real demand already — off-label prescribing in children aged 8 to 11 jumped from 0.03% to 9.3% in seven years, which means a label would formalize prescribing that is already happening. For Novo the trade read is defensive as much as offensive: the company has lost obesity ground to Lilly and just canceled several ziltivekimab cardiovascular trials, so a first-ever Phase 3 win in the 6-to-12 age group extends the semaglutide franchise at the exact moment its adult story is contested. The catalysts are dated and visible — detailed data at ObesityWeek, November 14 to 17, then a regulatory filing. Position sizing note: this is a label expansion for a drug already approved at 12 and up, so the revenue is incremental to the largest franchise in pharma, not transformative.

Mechanism and Market Context

The mechanism is unchanged from adult semaglutide — GLP-1 receptor agonism slowing gastric emptying and suppressing appetite — and that is the point: the biology scales down to children without modification. What is genuinely new is the trajectory question. Roughly 20.7% of US children aged 6 to 11 have obesity, and weight-related complications appear earlier and more severely in people who develop it young. A pediatric label positions semaglutide not as a weight-loss drug but as a disease-trajectory intervention, which is a different payer and policy conversation.

Risks and What Could Go Wrong

1. Detailed safety data, especially gastrointestinal effects in younger children, arrives at ObesityWeek — the press release is not the full dataset.
2. Sixty-eight weeks says nothing about durability or weight rebound after stopping in a developing child.
3. The regulatory filing is a year-plus from an approval decision, and pediatric obesity labels draw political attention.
4. Lilly is moving into pediatrics too, and the convenience fight could erase the first-mover halo quickly.